Hannani Dalil, Leplus Estelle, Laulagnier Karine, Chaperot Laurence, Plumas Joël
PDCline Pharma, Grenoble, France.
R&D Laboratory, Etablissement Français du Sang Auvergne Rhône-Alpes (EFS AURA), Grenoble, France.
Genes Cancer. 2023 Jan 30;14:3-11. doi: 10.18632/genesandcancer.229. eCollection 2023.
In recent years, immunotherapy has finally found its place in the anti-cancer therapeutic arsenal, even becoming standard of care as first line treatment for metastatic forms. The clinical benefit provided by checkpoint blockers such as anti-PD-1/PD-L1 in many cancers revolutionized the field. However, too many patients remain refractory to these treatments due to weak baseline anti-cancer immunity. There is therefore a need to boost the frequency and function of patients' cytotoxic CD8+ cellular effectors by targeting immunogenic and tumor-restricted antigens, such as neoantigens using an efficient vaccination platform. Dendritic cells (DC) are the most powerful immune cell subset for triggering cellular immune response. However, autologous DC-based vaccines display several limitations, such as the lack of reproducibility and the limited number of cells that can be manufactured. Here we discuss the advantages of a new therapeutic vaccine based on an allogeneic Plasmacytoid DC cell line, which is easy to produce and represents a powerful platform for priming and expanding anti-neoantigen cytotoxic CD8+ T-cells.
近年来，免疫疗法终于在抗癌治疗武器库中占据了一席之地，甚至成为转移性癌症一线治疗的标准疗法。抗PD-1/PD-L1等检查点阻断剂在许多癌症中提供的临床益处彻底改变了该领域。然而，由于基线抗癌免疫力较弱，太多患者对这些治疗仍不敏感。因此，需要通过使用高效的疫苗接种平台靶向免疫原性和肿瘤限制性抗原（如新抗原）来提高患者细胞毒性CD8+细胞效应器的频率和功能。树突状细胞（DC）是触发细胞免疫反应最强大的免疫细胞亚群。然而，基于自体DC的疫苗存在一些局限性，如缺乏可重复性以及可制造的细胞数量有限。在此，我们讨论一种基于同种异体浆细胞样DC细胞系的新型治疗性疫苗的优势，该疫苗易于生产，是启动和扩增抗新抗原细胞毒性CD8+ T细胞的强大平台。
